Skye Bioscience clinical trials we track

Check company identity source

Phase 2 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension) Measure: Part C - The nature, frequency, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs). After: Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension).

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 152 participants (planned). After: 136 participants (actual).

Check registry source

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent change in body weight. After: Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension) Measure: Part C - The nature, frequency, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs).

Planned enrollment increased by 32 participants

Before: 120 participants (planned). After: 152 participants (planned).

Primary completion date changed

Before: Aug 2025. After: 20 Nov 2026.

Check registry source